OncoSec Medical (NASDAQ:ONCS – Get Rating) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02, Fidelity Earnings reports.
ONCS opened at $0.80 on Thursday. The stock has a market capitalization of $31.49 million, a PE ratio of -0.77 and a beta of 2.03. OncoSec Medical has a 1-year low of $0.67 and a 1-year high of $4.25. The firm has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.97.
Institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna International Group LLP increased its position in OncoSec Medical by 62.7% in the 4th quarter. Susquehanna International Group LLP now owns 44,075 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 16,990 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in OncoSec Medical in the 3rd quarter valued at about $53,000. Bank of New York Mellon Corp acquired a new stake in OncoSec Medical in the 3rd quarter valued at about $109,000. Renaissance Technologies LLC increased its position in OncoSec Medical by 140.0% in the 4th quarter. Renaissance Technologies LLC now owns 249,361 shares of the biotechnology company’s stock valued at $239,000 after acquiring an additional 145,463 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in OncoSec Medical by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 262,478 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 17,467 shares in the last quarter. Hedge funds and other institutional investors own 13.98% of the company’s stock.
OncoSec Medical Company Profile (Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Wix.com Stock Nearing a Bottom Wick
- Home Depot May Have Value In The Long Term:
- A Game-Changing Deal For Blink Charging
- The Insiders Are Selling Chevron But You Shouldn’t
- Two Retailers The Analysts Are Buying
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.